{
    "nct_id": "NCT06158958",
    "official_title": "A Phase 1 First-in-Human, Open-Label Study Evaluating the Safety, Pharmacokinetics, and Efficacy of ABBV-303, as Monotherapy and in Combination With Budigalimab (ABBV-181), in Adult Subjects With Advanced Solid Tumors",
    "inclusion_criteria": "* Participants with Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.\n* Laboratory values meeting the protocol's criteria within the screening period (-28 days) prior to the first dose of study drug.\n* Participants with a diagnosis of a malignant solid tumor by histology (World Health Organization [WHO] criteria).\n* Participants with measurable disease per Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST v1.1).\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* Unresolved Grade > 1 adverse events (AEs) from prior anti-cancer therapy except for alopecia.\n* Active systemic or uncontrolled local bacterial, fungal, or viral infection requiring antimicrobial therapy.\n* History of hypersensitivity to the active ingredients or any excipients of ABBV-303 and budigalimab (ABBV-181).\n* Body weight < 35 kg.",
    "miscellaneous_criteria": ""
}